Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

Ettaib El Marabti, Ghaith Abu-Zeinah, Christopher Famulare, Ellen Ritchie, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2025-2026

Published: 2025

Journal Articles

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

Katie Erdos, Mlaak Rob, Majed Al-Nazer, Neville Lee, Joseph Scandura, Richard Silver, Ghaith Abu-Zeinah

Blood (2025) 146 (Supplement 1): 2043.

https://doi.org/10.1182/blood-2025-2043

Published: 2025

Journal Articles

Functional annotation of MPN clones reveals mutation-specific fitness and fate bias

Franco Castillo Tokumori, Daniel Choi, Ghaith Abu-Zeinah, Nassima Messali, Maria Yabut, Joseph Scandura

Blood (2025) 146 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2025-3766

Published: 2025

Journal Articles

Real-world temporal evaluation of static risk prediction in polycythemia vera

Katie Erdos, Neville Lee, Yushu Shi, Ghaith Abu-Zeinah, Joseph Scandura

Blood (2025) 146 (Supplement 1): 5594.

https://doi.org/10.1182/blood-2025-5594

Published: 2025

Journal Articles

Achieving JAK2V617F vaf <20% is associated with prolonged event-free survival in polycythemia vera: A milestone of molecular response

Franco Castillo Tokumori, Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Daniel Choi, Joseph Scandura

Blood (2025) 146 (Supplement 1): 5575.

https://doi.org/10.1182/blood-2025-5575

Published: 2025

Journal Articles

DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Yara Ganom, Christoph Klade, Kurt Krejcy, Heinz Gisslinger, Richard T. Silver, Joseph M. Scandura

Blood (2025) 146 (1): 123–126.

https://doi.org/10.1182/blood.2024027528

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2024-200997

Published: 2024

Journal Articles

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John O. Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 3191.1.

https://doi.org/10.1182/blood-2024-200319

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Neville Lee, Jr., Katie Erdos, Aqib Abdul Rahman, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2024-211143

Published: 2024

Journal Articles

Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera

Katie Erdos, Neville Lee, Jr., Yushu Shi, Ghaith Abu-Zeinah, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2024-210632

Published: 2024

Journal Articles

Deep Learning Predicts JAK2 , Calr TET2 , and ASXL1 directly from Whole Slide Marrow Images

Spencer Krichevsky, Yuwei Zhang, Madhu M Ouseph, Tahmeena Ahmed, Ghaith Abu-Zeinah, Joseph M. Scandura, Rajarsi Gupta

Blood (2024) 144 (Supplement 1): 3600.

https://doi.org/10.1182/blood-2024-208380

Published: 2024

Journal Articles

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Abdulraheem Yacoub, Ghaith Abu-Zeinah, Albert Qin, Weichung Joe Shih, Waleed Da'na, Tsewang Tashi, Oleh Zagrijtschuk, Robert Geller, Harinder Gill

Blood (2024) 144 (Supplement 1): 6626.

https://doi.org/10.1182/blood-2024-199337

Published: 2024

Journal Articles

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Daniel C Choi, Nassima Messali, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Franco Castillo Tokumori, Katie Erdos, Joseph M. Scandura, Narasimha Rao Uda, Heidi Lischer, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao

Blood (2024) 144 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2024-212169

Published: 2024

Journal Articles

Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

Alexander Gazda, Di Pan, Katie Erdos, Ghaith Abu-Zeinah, Alexandra Racanelli, Evelyn Horn, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3172.

https://doi.org/10.1182/blood-2024-210231

Published: 2024

Journal Articles

Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms

Spencer Krichevsky, Madhu M Ouseph, Yuwei Zhang, Tahmeena Ahmed, Ghaith Abu-Zeinah, Joseph M. Scandura, Rajarsi Gupta

Blood (2024) 144 (Supplement 1): 3613.

https://doi.org/10.1182/blood-2024-208329

Published: 2024

Journal Articles

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Jr., Richard T. Silver, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2024-210703

Published: 2024

Journal Articles

MPN Fitness: A Single-Cell, Single-Tube Measurement of the Pathobiology of MPNs

Franco Castillo Tokumori, Daniel C Choi, Ghaith Abu-Zeinah, Nassima Messali, Maria Mia Yabut, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2024-209523

Published: 2024

Journal Articles

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

Spencer Krichevsky, Ghaith Abu-Zeinah, Katie Erdos, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2023-190684

Published: 2023

Journal Articles

JAK2 V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms

Daniel C Choi, Ghaith Abu-Zeinah, Pouneh Kermani, Nassima Messali, Maria Mia Yabut, Katie Erdos, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 1778.

https://doi.org/10.1182/blood-2023-190758

Published: 2023

Journal Articles

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Katie Erdos, Madhu M Ouseph, Julia Geyer, Neville Lee, Jr., Ghaith Abu-Zeinah, Joseph M. Scandura, Richard T. Silver

Blood (2023) 142 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2023-187769

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival

Functional annotation of MPN clones reveals mutation-specific fitness and fate bias

Real-world temporal evaluation of static risk prediction in polycythemia vera

Achieving JAK2V617F vaf <20% is associated with prolonged event-free survival in polycythemia vera: A milestone of molecular response

DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera

Deep Learning Predicts JAK2 , Calr TET2 , and ASXL1 directly from Whole Slide Marrow Images

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

MPN Fitness: A Single-Cell, Single-Tube Measurement of the Pathobiology of MPNs

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

JAK2 V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only